|
CN106432184A
|
|
Trelagliptin derivative and application tereof
|
|
CN105837555A
|
|
Preparation method for garenoxacin and intermediate thereof
|
|
CN105523994A
|
|
Crystal form III of lomitapide mesylate
|
|
CN105461618A
|
|
New crystal forms of lomitapide mesylate and preparation method thereof
|
|
CN105481779A
|
|
Anti-cancer drug Rociletinib and preparation of intermediate thereof
|
|
CN105503865A
|
|
Novel pyrazolopyridine antineoplastic compound
|
|
CN105503863A
|
|
Novel anti-tumor compound
|
|
CN106562968A
|
|
Pharmaceutical composition containing tamsulosin hydrochloride and solifenacin succinate
|
|
CN106542973A
|
|
Ta Simeiqiong intermediates and preparation method thereof
|
|
CN106478531A
|
|
2- (the bromo- 4- of 5- (4- cyclopropyl naphthalene -1- base) -4H-1,2,4- triazole -3- base sulfenyls) acid intermediates
|
|
CN106467519A
|
|
A kind of water-soluble triazole compound
|
|
CN106432042A
|
|
New medicine crystal form of nintedanib ethanesulfonate hydrate
|
|
CN105399742A
|
|
Nagelieting crystal form A and pharmaceutical composition
|
|
CN105395552A
|
|
Solid preparation containing fimasartan and salt thereof
|
